ADHD

From the normalization of burnout to the identification of sleep-wake disturbances post-TBI, here are highlights from the week in Psychiatric Times.

Results show that the novel formulation of dexmethylphenidate can be taken either with or without food.

How do you “see” your patients with ADHD? Researchers performed a systematic review and meta-analysis of ADHD and vision problems.

From the effects of caffeine on smokers with schizophrenia and bipolar disorder to the initiation of a trial for a new ADHD medication, here are highlights from the week in Psychiatric Times.

The first phase 3 clinical trial of CTx-1301 for the treatment of ADHD has begun.

From new advances in the treatment of postpartum depression to digital therapeutics for the treatment of ADHD in children, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the December 2022 issue of Psychiatric Times.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

The investigators suggested that future research explore the connection between ADHD risk in children and depression in pregnant parents.

Take a look at this bread-and-butter case of ADHD from a child psychiatry clinic.

Screening for the symptom of worthlessness could save your adolescent patient’s life…

The experts weighed in on a wide variety of psychiatric issues for the November 2022 issue of Psychiatric Times.

Experts in attention-deficit/hyperactivity disorder discuss future nonmedication interventions, like trigeminal nerve stimulation and digital therapeutics.

Theresa Cerulli, MD, discusses the practical considerations for using serdexmethylphenidate-dexmethylphenidate for the treatment of attention-deficit/hyperactivity disorder.

What are the advances in adult ADHD?

Theresa Cerulli, MD, describes the indication and mechanism of the recent FDA approved combination product serdexmethylphenidate /dexmethylphenidate for the treatment of attention deficit/hyperactivity disorder (ADHD).

Experts in attention-deficit/hyperactivity disorder (ADHD) discuss how to determine treatment failure in adults and the benefit of different dosing strategies for therapeutic options.

ADHD is an all-day affair, and treating it in an adult population can be difficult.

Theresa Cerulli, MD, and Anthony Rostain, MD, MA, discuss challenges with substance abuse related to pharmacologic interventions for adult attention-deficit/hyperactivity disorder (ADHD) treatment.

Experts in treatment of attention-deficit/hyperactivity disorder discuss the benefits of different drug formulations and the potential for abuse of immediate-release medications.

Anthony Rostain, MD, MA, provides an overview of stimulants, nonstimulants, amphetamines, and methylphenidates for adult attention-deficit/hyperactivity disorder (ADHD) treatment.

Experts in attention-deficit/hyperactivity disorder (ADHD) discuss the importance of patient education and shared decision-making in working toward treatment goals.

From complementary and alternative approaches in the COVID-19 era to mental health’s most toxic myth, here are highlights from the week in Psychiatric Times.

Drs Stephen Faraone, Theresa Cerulli, Craig Chepke, and Andrew J. Cutler discuss novel drug delivery systems and provide take-home messages when treating an adult with ADHD.

Stephen Faraone, PhD; Theresa Cerulli, MD; Craig Chepke, MD, FAPA; and Andrew J. Cutler, MD, discuss implications of pharmacogenetic testing in ADHD.